Therefore, it would be beneficial for patients with scarring alopecia, irrespective of the type, to screen for therapeutic markers highlighting JAK-STAT1 activity or JAK-inhibitor sensitivity to predict treatment efficiency or success. Here, STAT1 is linked to alopecia.